Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | PER2 | O15055 | 2/20 | 0.44 |
| ▸ | CRY1 | Q16526 | 2/20 | 0.44 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291402 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2PER2CRY1CRY2ALDH1A1 | |
| SCHEMBL18291553 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2PER2CRY1CRY2ALDH1A1 | |
| SCHEMBL20037844 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2PER2CRY1CRY2ALDH1A1 | |
| SCHEMBL20037789 | 0.86 | SMN1; SMN2 (0.46) | SMN1; SMN2PER2CRY1CRY2ALDH1A1 | |
| SCHEMBL20249120 | 0.84 | ALDH1A1 (0.45) | SMN1; SMN2PER2CRY1CRY2ALDH1A1 | |
| SCHEMBL20249123 | 0.84 | ALDH1A1 (0.45) | SMN1; SMN2PER2CRY1CRY2ALDH1A1 | |
| SCHEMBL18291401 | 0.81 | FFAR2 (0.35) | SMN1; SMN2HTT | |
| SCHEMBL18291731 | 0.80 | OXTR (0.48) | POLBGAAOXTRAVPR1A | |
| SCHEMBL18291743 | 0.80 | OXTR (0.48) | POLBGAAOXTRAVPR1A | |
| SCHEMBL18291418 | 0.70 | SLC6A2 (0.37) | PER2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | SMN1; SMN2 1690/4885PER2 2006/4885CRY1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.